Results 121 to 130 of about 2,065,768 (386)

Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study [PDF]

, 2023
Yu-Cing Jhuo, Tai‐Lung Cha, Chien‐Chang Kao, Yi-Ta Tsai, Sheng‐Tang Wu, En Meng, Chih‐Wei Tsao, Chin-Li Chen, Hui-Kung Ting, Guang‐Huan Sun, Dah‐Shyong Yü, Sun‐Yran Chang, Ming-Hsin Yang   +12 more
openalex   +1 more source

A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells

Nature Communications, 2019
Circulating tumor cells (CTCs) have become an established biomarker for prognosis in patients with various carcinomas. However, current ex vivo CTC isolation technologies rely on small blood volumes from a single venipuncture limiting the number of ...
Tae Hyun Kim, Yang Wang, C. Oliver, D. Thamm, L. Cooling, C. Paoletti, K. Smith, S. Nagrath, Daniel F. Hayes   +8 more
semanticscholar   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. [PDF]

, 2018
Both adjuvants and focal ablation can alter the local innate immune system and trigger a highly effective systemic response. Our goal is to determine the impact of these treatments on directly treated and distant disease and the mechanisms for the ...
Borowsky, Alexander D, Chavez, Michael, Davis, Ryan R, Ferrara, Katherine W, Fite, Brett Z, Hubbard, Neil E, Ilovitsh, Asaf, Ingham, Elizabeth S, Mahakian, Lisa M, Monjazeb, Arta M, Murphy, William J, Silvestrini, Matthew T, Tam, Sarah M, Tepper, Clifford G   +13 more
core   +1 more source

Circulating tumor cells exhibit metastatic tropism and reveal brain metastasis drivers.

Cancer Discovery, 2019
Hematogenous metastasis is initiated by a subset of circulating tumor cells (CTCs) shed from primary or metastatic tumors into the blood circulation.
Remi Klotz, Amal Thomas, Teng Teng, S. M. Han, Oihana Iriondo, Lin Li, Sara Restrepo-Vassalli, Alan Wang, Negeen Izadian, M. MacKay, Byoung-San Moon, Kevin J Liu, S. K. Ganesan, Grace Lee, Diane Kang, C. Walmsley, C. Pinto, M. Press, W. Lu, Janice M. Lu, D. Juric, A. Bardia, J. Hicks, B. Salhia, F. Attenello, Andrew D. Smith, Min Yu   +26 more
semanticscholar   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Epithelial-mesenchymal transition of circulating tumor cells in prostate cancer is promoted by survivin [PDF]

, 2020
Faying Yang, Jianhua Ma, Jianghou Wan, Wuhua Ha, Cheng Fang, Huaiquan Lu, Wei Zhang   +6 more
openalex   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Deterministic Separation of Cancer Cells from Blood at 10 mL/min [PDF]

, 2012
Circulating tumor cells (CTCs) and circulating clusters of cancer and stromal cells have been identified in the blood of patients with malignant cancer and can be used as a diagnostic for disease severity, assess the efficacy of different treatment ...
Amy Wu, James Sturm, Joseph D', Kevin Loutherback, Liyu Liu, Robert Austin   +5 more
core   +3 more sources

Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.

Cancer Research, 2018
To clarify the significance of circulating tumor cells (CTC) undergoing epithelial-mesenchymal transition (EMT) in patients with hepatocellular carcinoma (HCC), we used an advanced CanPatrol CTC-enrichment technique and in situ hybridization to enrich ...
Lu-Nan Qi, B. Xiang, Fei-Xiang Wu, J. Ye, J. Zhong, Yan-Yan Wang, Yuan-yuan Chen, Zushun Chen, Liang Ma, Jie Chen, W. Gong, Ze-Guang Han, Yan Lu, Jin-Jie Shang, Lequn Li   +14 more
semanticscholar   +1 more source